N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity
Reactive oxygen species formation and release of pro-inflammatory/pro-atherogenic cytokines, that is, interleukin 1-β and tumor necrosis factor-α, need the activation of the arachidonic acid cascade via the enzyme 5-lipoxygenase (5-Lox). 5-Lox activity and expression are significantly increased in p...
Gespeichert in:
| Veröffentlicht in: | Kidney international 2006-04, Vol.69 (8), p.1450-1454 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1454 |
|---|---|
| container_issue | 8 |
| container_start_page | 1450 |
| container_title | Kidney international |
| container_volume | 69 |
| creator | Taccone-Gallucci, M. Manca-di-Villahermosa, S. Battistini, L. Stuffler, R.G. Tedesco, M. Maccarrone, M. |
| description | Reactive oxygen species formation and release of pro-inflammatory/pro-atherogenic cytokines, that is, interleukin 1-β and tumor necrosis factor-α, need the activation of the arachidonic acid cascade via the enzyme 5-lipoxygenase (5-Lox). 5-Lox activity and expression are significantly increased in peripheral blood mononuclear cells (PBMCs) of end-stage renal disease (ESRD) patients on maintenance hemodialysis (HD). Diets enriched with n-3 polyunsaturated fatty acids (PUFAs) (ω-3) have been associated to a lower incidence of coronary heart disease (CHD) and a reduction in atherosclerotic lesions. Ω-3 may interfere with the arachidonic acid cascade by inhibiting 5-Lox. Lipid peroxidation, leukotriene B4 (LTB4) production, 5-Lox activity and expression were investigated in PBMC isolated from ESRD patients under maintenance HD before and after a 3-month oral supplementation with ω-3 at a daily dose of 2700 mg of n-3 PUFAs at the average eicosapentaenoic acid/docosaesaenoic acid ratio of 1.2 and finally after a further 3-month washout with no ω-3 supplementation. PBMCs from non-uremic volunteers were also investigated for comparison to normal parameters. Administration of ω-3 reduced significantly lipid peroxidation (P |
| doi_str_mv | 10.1038/sj.ki.5000291 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67858253</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0085253815516724</els_id><sourcerecordid>67858253</sourcerecordid><originalsourceid>FETCH-LOGICAL-c501t-ff8c77e7c27e360282e103e0806aae6b3a0f81dddb4aa82e6e90c0ea8b5c86523</originalsourceid><addsrcrecordid>eNp10U1r3DAQBmBRWppN2mOvRRSam7eSvbK0x5DPQkhK25yFLI9TOV55q5FD9t9nwhoChZ4E0qNh5h3GPkmxlKIy37BfPoSlEkKUa_mGLaQqq0Jqpd6yhRBGFaWqzAE7ROzJmHUl3rMDWatKrs1qwfqbouI_7i5OkCdoJw98fAqty-EROOYEiDxEfv7r5xnf0i3EjHyMfONCzBBdpA9XZ7zZkfoTmpBDvOeqGMJ2fNrdE0DgzlO1kHcf2LvODQgf5_OI3V2c_z69Kq5vL7-fnlwXXgmZi64zXmvQvtRQ1aI0JdCgIIyonYO6qZzojGzbtlk5R481rIUX4EyjvKlp-iN2vK-7TePfCTDbTUAPw-AijBPaWhtlKBWCX_6B_TilSL3ZUgoptDY1oWKPfBoRE3R2m8LGpZ2Vwr5swGJvH4KdN0D-81x0ajbQvuo5cgJfZ-DQu6FLFGLAV6f1Sq_USyG9d0BZPQZIFj3l76ENCXy27Rj-08IzWq2hLQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>210107786</pqid></control><display><type>article</type><title>N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Taccone-Gallucci, M. ; Manca-di-Villahermosa, S. ; Battistini, L. ; Stuffler, R.G. ; Tedesco, M. ; Maccarrone, M.</creator><creatorcontrib>Taccone-Gallucci, M. ; Manca-di-Villahermosa, S. ; Battistini, L. ; Stuffler, R.G. ; Tedesco, M. ; Maccarrone, M.</creatorcontrib><description>Reactive oxygen species formation and release of pro-inflammatory/pro-atherogenic cytokines, that is, interleukin 1-β and tumor necrosis factor-α, need the activation of the arachidonic acid cascade via the enzyme 5-lipoxygenase (5-Lox). 5-Lox activity and expression are significantly increased in peripheral blood mononuclear cells (PBMCs) of end-stage renal disease (ESRD) patients on maintenance hemodialysis (HD). Diets enriched with n-3 polyunsaturated fatty acids (PUFAs) (ω-3) have been associated to a lower incidence of coronary heart disease (CHD) and a reduction in atherosclerotic lesions. Ω-3 may interfere with the arachidonic acid cascade by inhibiting 5-Lox. Lipid peroxidation, leukotriene B4 (LTB4) production, 5-Lox activity and expression were investigated in PBMC isolated from ESRD patients under maintenance HD before and after a 3-month oral supplementation with ω-3 at a daily dose of 2700 mg of n-3 PUFAs at the average eicosapentaenoic acid/docosaesaenoic acid ratio of 1.2 and finally after a further 3-month washout with no ω-3 supplementation. PBMCs from non-uremic volunteers were also investigated for comparison to normal parameters. Administration of ω-3 reduced significantly lipid peroxidation (P<0.0001), LTB4 synthesis (P<0.0001) and 5-Lox activity (P<0.0001), with no effect on 5-Lox protein expression. After the 3-month washout, all parameters were comparable to those observed before treatment. Our results resemble those obtained after oral administration of vitamin E and are consistent with a reversible, dose-dependent inhibition of 5-Lox by ω-3. Upregulation of 5-Lox may also be related to the increased mitochondrial damage and apoptosis of PBMCs observed in ESRD patients compared to non-uremic controls. Ω-3 may thus protect PBMCs of ESRD patients against oxidative stress.</description><identifier>ISSN: 0085-2538</identifier><identifier>EISSN: 1523-1755</identifier><identifier>DOI: 10.1038/sj.ki.5000291</identifier><identifier>PMID: 16531984</identifier><identifier>CODEN: KDYIA5</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>5-lipoxygenase ; Aged ; Apoptosis ; Arachidonate 5-Lipoxygenase - genetics ; Arachidonate 5-Lipoxygenase - metabolism ; atherosclerosis ; Atherosclerosis (general aspects, experimental research) ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Case-Control Studies ; Fatty Acids, Omega-3 - therapeutic use ; Gene Expression ; hemodialysis ; Humans ; Kidney Failure, Chronic - drug therapy ; Kidney Failure, Chronic - metabolism ; Leukocytes, Mononuclear - drug effects ; Leukocytes, Mononuclear - enzymology ; Leukotriene B4 - analysis ; Lipid Peroxidation - drug effects ; Lipoxygenase Inhibitors ; Medical sciences ; Middle Aged ; N-3 PUFAs ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; oxidative stress ; Oxidative Stress - drug effects ; Renal Dialysis ; Renal failure</subject><ispartof>Kidney international, 2006-04, Vol.69 (8), p.1450-1454</ispartof><rights>2006 International Society of Nephrology</rights><rights>2006 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Apr 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c501t-ff8c77e7c27e360282e103e0806aae6b3a0f81dddb4aa82e6e90c0ea8b5c86523</citedby><cites>FETCH-LOGICAL-c501t-ff8c77e7c27e360282e103e0806aae6b3a0f81dddb4aa82e6e90c0ea8b5c86523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/210107786?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17747451$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16531984$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taccone-Gallucci, M.</creatorcontrib><creatorcontrib>Manca-di-Villahermosa, S.</creatorcontrib><creatorcontrib>Battistini, L.</creatorcontrib><creatorcontrib>Stuffler, R.G.</creatorcontrib><creatorcontrib>Tedesco, M.</creatorcontrib><creatorcontrib>Maccarrone, M.</creatorcontrib><title>N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity</title><title>Kidney international</title><addtitle>Kidney Int</addtitle><description>Reactive oxygen species formation and release of pro-inflammatory/pro-atherogenic cytokines, that is, interleukin 1-β and tumor necrosis factor-α, need the activation of the arachidonic acid cascade via the enzyme 5-lipoxygenase (5-Lox). 5-Lox activity and expression are significantly increased in peripheral blood mononuclear cells (PBMCs) of end-stage renal disease (ESRD) patients on maintenance hemodialysis (HD). Diets enriched with n-3 polyunsaturated fatty acids (PUFAs) (ω-3) have been associated to a lower incidence of coronary heart disease (CHD) and a reduction in atherosclerotic lesions. Ω-3 may interfere with the arachidonic acid cascade by inhibiting 5-Lox. Lipid peroxidation, leukotriene B4 (LTB4) production, 5-Lox activity and expression were investigated in PBMC isolated from ESRD patients under maintenance HD before and after a 3-month oral supplementation with ω-3 at a daily dose of 2700 mg of n-3 PUFAs at the average eicosapentaenoic acid/docosaesaenoic acid ratio of 1.2 and finally after a further 3-month washout with no ω-3 supplementation. PBMCs from non-uremic volunteers were also investigated for comparison to normal parameters. Administration of ω-3 reduced significantly lipid peroxidation (P<0.0001), LTB4 synthesis (P<0.0001) and 5-Lox activity (P<0.0001), with no effect on 5-Lox protein expression. After the 3-month washout, all parameters were comparable to those observed before treatment. Our results resemble those obtained after oral administration of vitamin E and are consistent with a reversible, dose-dependent inhibition of 5-Lox by ω-3. Upregulation of 5-Lox may also be related to the increased mitochondrial damage and apoptosis of PBMCs observed in ESRD patients compared to non-uremic controls. Ω-3 may thus protect PBMCs of ESRD patients against oxidative stress.</description><subject>5-lipoxygenase</subject><subject>Aged</subject><subject>Apoptosis</subject><subject>Arachidonate 5-Lipoxygenase - genetics</subject><subject>Arachidonate 5-Lipoxygenase - metabolism</subject><subject>atherosclerosis</subject><subject>Atherosclerosis (general aspects, experimental research)</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Case-Control Studies</subject><subject>Fatty Acids, Omega-3 - therapeutic use</subject><subject>Gene Expression</subject><subject>hemodialysis</subject><subject>Humans</subject><subject>Kidney Failure, Chronic - drug therapy</subject><subject>Kidney Failure, Chronic - metabolism</subject><subject>Leukocytes, Mononuclear - drug effects</subject><subject>Leukocytes, Mononuclear - enzymology</subject><subject>Leukotriene B4 - analysis</subject><subject>Lipid Peroxidation - drug effects</subject><subject>Lipoxygenase Inhibitors</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>N-3 PUFAs</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Renal Dialysis</subject><subject>Renal failure</subject><issn>0085-2538</issn><issn>1523-1755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp10U1r3DAQBmBRWppN2mOvRRSam7eSvbK0x5DPQkhK25yFLI9TOV55q5FD9t9nwhoChZ4E0qNh5h3GPkmxlKIy37BfPoSlEkKUa_mGLaQqq0Jqpd6yhRBGFaWqzAE7ROzJmHUl3rMDWatKrs1qwfqbouI_7i5OkCdoJw98fAqty-EROOYEiDxEfv7r5xnf0i3EjHyMfONCzBBdpA9XZ7zZkfoTmpBDvOeqGMJ2fNrdE0DgzlO1kHcf2LvODQgf5_OI3V2c_z69Kq5vL7-fnlwXXgmZi64zXmvQvtRQ1aI0JdCgIIyonYO6qZzojGzbtlk5R481rIUX4EyjvKlp-iN2vK-7TePfCTDbTUAPw-AijBPaWhtlKBWCX_6B_TilSL3ZUgoptDY1oWKPfBoRE3R2m8LGpZ2Vwr5swGJvH4KdN0D-81x0ajbQvuo5cgJfZ-DQu6FLFGLAV6f1Sq_USyG9d0BZPQZIFj3l76ENCXy27Rj-08IzWq2hLQ</recordid><startdate>20060401</startdate><enddate>20060401</enddate><creator>Taccone-Gallucci, M.</creator><creator>Manca-di-Villahermosa, S.</creator><creator>Battistini, L.</creator><creator>Stuffler, R.G.</creator><creator>Tedesco, M.</creator><creator>Maccarrone, M.</creator><general>Elsevier Inc</general><general>Nature Publishing</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20060401</creationdate><title>N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity</title><author>Taccone-Gallucci, M. ; Manca-di-Villahermosa, S. ; Battistini, L. ; Stuffler, R.G. ; Tedesco, M. ; Maccarrone, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c501t-ff8c77e7c27e360282e103e0806aae6b3a0f81dddb4aa82e6e90c0ea8b5c86523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>5-lipoxygenase</topic><topic>Aged</topic><topic>Apoptosis</topic><topic>Arachidonate 5-Lipoxygenase - genetics</topic><topic>Arachidonate 5-Lipoxygenase - metabolism</topic><topic>atherosclerosis</topic><topic>Atherosclerosis (general aspects, experimental research)</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Case-Control Studies</topic><topic>Fatty Acids, Omega-3 - therapeutic use</topic><topic>Gene Expression</topic><topic>hemodialysis</topic><topic>Humans</topic><topic>Kidney Failure, Chronic - drug therapy</topic><topic>Kidney Failure, Chronic - metabolism</topic><topic>Leukocytes, Mononuclear - drug effects</topic><topic>Leukocytes, Mononuclear - enzymology</topic><topic>Leukotriene B4 - analysis</topic><topic>Lipid Peroxidation - drug effects</topic><topic>Lipoxygenase Inhibitors</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>N-3 PUFAs</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Renal Dialysis</topic><topic>Renal failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taccone-Gallucci, M.</creatorcontrib><creatorcontrib>Manca-di-Villahermosa, S.</creatorcontrib><creatorcontrib>Battistini, L.</creatorcontrib><creatorcontrib>Stuffler, R.G.</creatorcontrib><creatorcontrib>Tedesco, M.</creatorcontrib><creatorcontrib>Maccarrone, M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Kidney international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taccone-Gallucci, M.</au><au>Manca-di-Villahermosa, S.</au><au>Battistini, L.</au><au>Stuffler, R.G.</au><au>Tedesco, M.</au><au>Maccarrone, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity</atitle><jtitle>Kidney international</jtitle><addtitle>Kidney Int</addtitle><date>2006-04-01</date><risdate>2006</risdate><volume>69</volume><issue>8</issue><spage>1450</spage><epage>1454</epage><pages>1450-1454</pages><issn>0085-2538</issn><eissn>1523-1755</eissn><coden>KDYIA5</coden><abstract>Reactive oxygen species formation and release of pro-inflammatory/pro-atherogenic cytokines, that is, interleukin 1-β and tumor necrosis factor-α, need the activation of the arachidonic acid cascade via the enzyme 5-lipoxygenase (5-Lox). 5-Lox activity and expression are significantly increased in peripheral blood mononuclear cells (PBMCs) of end-stage renal disease (ESRD) patients on maintenance hemodialysis (HD). Diets enriched with n-3 polyunsaturated fatty acids (PUFAs) (ω-3) have been associated to a lower incidence of coronary heart disease (CHD) and a reduction in atherosclerotic lesions. Ω-3 may interfere with the arachidonic acid cascade by inhibiting 5-Lox. Lipid peroxidation, leukotriene B4 (LTB4) production, 5-Lox activity and expression were investigated in PBMC isolated from ESRD patients under maintenance HD before and after a 3-month oral supplementation with ω-3 at a daily dose of 2700 mg of n-3 PUFAs at the average eicosapentaenoic acid/docosaesaenoic acid ratio of 1.2 and finally after a further 3-month washout with no ω-3 supplementation. PBMCs from non-uremic volunteers were also investigated for comparison to normal parameters. Administration of ω-3 reduced significantly lipid peroxidation (P<0.0001), LTB4 synthesis (P<0.0001) and 5-Lox activity (P<0.0001), with no effect on 5-Lox protein expression. After the 3-month washout, all parameters were comparable to those observed before treatment. Our results resemble those obtained after oral administration of vitamin E and are consistent with a reversible, dose-dependent inhibition of 5-Lox by ω-3. Upregulation of 5-Lox may also be related to the increased mitochondrial damage and apoptosis of PBMCs observed in ESRD patients compared to non-uremic controls. Ω-3 may thus protect PBMCs of ESRD patients against oxidative stress.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>16531984</pmid><doi>10.1038/sj.ki.5000291</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0085-2538 |
| ispartof | Kidney international, 2006-04, Vol.69 (8), p.1450-1454 |
| issn | 0085-2538 1523-1755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67858253 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
| subjects | 5-lipoxygenase Aged Apoptosis Arachidonate 5-Lipoxygenase - genetics Arachidonate 5-Lipoxygenase - metabolism atherosclerosis Atherosclerosis (general aspects, experimental research) Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system Case-Control Studies Fatty Acids, Omega-3 - therapeutic use Gene Expression hemodialysis Humans Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - metabolism Leukocytes, Mononuclear - drug effects Leukocytes, Mononuclear - enzymology Leukotriene B4 - analysis Lipid Peroxidation - drug effects Lipoxygenase Inhibitors Medical sciences Middle Aged N-3 PUFAs Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure oxidative stress Oxidative Stress - drug effects Renal Dialysis Renal failure |
| title | N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T21%3A07%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=N-3%20PUFAs%20reduce%20oxidative%20stress%20in%20ESRD%20patients%20on%20maintenance%20HD%20by%20inhibiting%205-lipoxygenase%20activity&rft.jtitle=Kidney%20international&rft.au=Taccone-Gallucci,%20M.&rft.date=2006-04-01&rft.volume=69&rft.issue=8&rft.spage=1450&rft.epage=1454&rft.pages=1450-1454&rft.issn=0085-2538&rft.eissn=1523-1755&rft.coden=KDYIA5&rft_id=info:doi/10.1038/sj.ki.5000291&rft_dat=%3Cproquest_cross%3E67858253%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=210107786&rft_id=info:pmid/16531984&rft_els_id=S0085253815516724&rfr_iscdi=true |